- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01253278
A Multiple-Ascending Dose Study in Type 2 Diabetes Mellitus Patients
June 9, 2011 updated by: Eli Lilly and Company
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Oral Doses of LY2393910 in Patients With Type 2 Diabetes Mellitus
The study drug LY2393910 is being evaluated as a possible treatment for diabetes. The primary purpose of a patient's participation in this study is to help answer the following research question(s), and not to provide treatment for diabetes:
- The safety of LY2393910 and any side effects that might be associated with it following 2 weeks of doses
- How long it takes the body to absorb and remove LY2393910 following dosing over 2 weeks
- How daily dosing of LY2393910 affects blood levels of sugar (glucose), insulin and other naturally occurring substances in your body
- How daily dosing of LY2393910 affects the cells that produce insulin
- Any differences in the above between LY2393910 taken as daily doses in the morning or in the evening
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Neuss, Germany, D-41460
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosis of type 2 diabetes mellitus
- Must be on a stable treatment regimen (maintained on diet/exercise therapy with or without metformin) for at least 4 weeks prior to study entry
- Have a glycated haemoglobin (HbA1c) value greater than or equal to 6.5% and less than or equal to 10.0% on a stable treatment regimen
- Weigh 45.0 kg or more
- Have a Body Mass Index (BMI) greater than or equal to 18.5 and less than or equal to 40.0 kg/m2
- Are willing and able to conduct self-blood glucose monitoring tests
Exclusion Criteria:
- Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving use of an investigational drug or device other than the study drug used in this study, or are concurrently enrolled in any other type of medical research judged not to be compatible with this study
- Use of insulin for diabetic control for more than 6 consecutive days within 1 year prior to study entry
- Use of thiazolidinediones within 3 months, or other oral anti-diabetics (OADs), apart from metformin, within 1 month prior to study entry. Metformin is acceptable for this study
- Previous myocardial infarction, stroke or transient ischaemic event ('TIA'), or clinically significant coronary events or symptoms within 6 months prior to study entry
- Subjects who have any evidence of heart insufficiency, hypokalaemia, family history of long-QT-syndrome or are receiving other drugs which extend the QT interval
- Clinically significant peripheral vascular disease
- Clinical evidence of active diabetic proliferative retinopathy
- Known significant autonomic neuropathy
- Any patient having experienced a keto-acidotic episode requiring hospitalisation in the last 6 months
- Symptomatic hyperglycemia exhibited by significant osmotic symptoms (polyuria or polydipsia), unanticipated weight loss or dehydration
- Evidence of hepatitis B and/or positive hepatitis B surface antigen, at screening
- Subjects who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females)
- Subjects who are heavy smokers (> 10 cigarettes, or equivalent, per day) or are unable or unwilling to refrain from nicotine during CRU admissions
Exclusion Criteria for EU Site only --
- Regular use of known drugs of abuse and/or positive findings on urinary drug screening
- Evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies
- Evidence of hepatitis C and/or positive hepatitis C antibodies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
as capsules, administered orally once daily for two weeks
|
Experimental: 20 mg LY2393910
|
as capsules, administered orally once daily for two weeks
|
Experimental: 60 mg LY2393910
|
as capsules, administered orally once daily for two weeks
|
Experimental: 150 mg LY2393910
|
as capsules, administered orally once daily for two weeks
|
Experimental: 450 mg LY2393910
|
as capsules, administered orally once daily for two weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants with Clinically Significant Effects
Time Frame: Over four weeks
|
Over four weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of LY2393910, Area Under the Curve (AUC)
Time Frame: From predose Day 1 up until Day 19
|
From predose Day 1 up until Day 19
|
Change from baseline to day 28 in glucagon
Time Frame: Baseline, day 28
|
Baseline, day 28
|
Pharmacokinetics of LY2393910, maximum concentration (Cmax)
Time Frame: From predose Day 1 up until Day 19
|
From predose Day 1 up until Day 19
|
Change from baseline to day 28 in glucose-like peptide 1 (GLP-1)
Time Frame: Baseline, day 28
|
Baseline, day 28
|
Change from baseline to day 14 in insulin
Time Frame: baseline, day 14
|
baseline, day 14
|
Change from baseline to day 14 in proinsulin
Time Frame: baseline, day 14
|
baseline, day 14
|
Change from baseline to day 28 in glucose
Time Frame: baseline, day 28
|
baseline, day 28
|
Change from baseline to day 14 in C-peptide
Time Frame: baseline, day 14
|
baseline, day 14
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2010
Primary Completion (Actual)
May 1, 2011
Study Completion (Actual)
May 1, 2011
Study Registration Dates
First Submitted
December 1, 2010
First Submitted That Met QC Criteria
December 1, 2010
First Posted (Estimate)
December 3, 2010
Study Record Updates
Last Update Posted (Estimate)
June 10, 2011
Last Update Submitted That Met QC Criteria
June 9, 2011
Last Verified
June 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13183
- I4B-FW-GPCB (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China